Trial Profile

Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR 105 (Primary)
Indications Pneumonia; Ventilator associated pneumonia
Focus Adverse reactions; First in man
Sponsors Aridis Pharmaceuticals

Most Recent Events

07 Jan 2016 Results published in the Media Release
29 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to completed.
30 Jun 2015 According to an Aridis Pharmaceuticals media release, Aerucin has received fast-track designation for treating hospital-acquired and ventilator-associated pneumonia. Results from this trial are expected in the fourth quarter of 2015.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com